Back to search

Peptide record

TPDB09277

Antibacterial Antifungal Hemolysis Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09277
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 20-aa standard-residue multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
AKKVFKRLGIGAVLWVLTTG
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C103H173N27O23
NDCEQHMPSY
GLKV
2157.67
11.73
4
0
11
+4
-0.34
0.760
131.50
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
5500
2.55
2
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
0
Q
3
G
0
H
1
I
3
L
3
K
0
M
1
F
0
P
0
S
2
T
1
W
0
Y
3
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 1 L: 3 K: 3 M: 0 F: 1 P: 0 S: 0 T: 2 W: 1 Y: 0 V: 3
Chemical Descriptors
20 reviewed residue count
C103H173N27O23 sequence-only estimate (linear, free termini)
2157.67 sequence-only estimate (linear, free termini)
11.73 sequence-only estimate (linear, free termini)
+4 sequence-only estimate (linear, free termini)
-0.34 sequence-only estimate (linear, free termini)
0.760 sequence-only estimate (linear, free termini)
Evidence Records 6 records
Evidence 1 Activity

Activity

0% Hemolysis
Toxicity
6.25 µM
Hemolytic Cytotoxic
0% Hemolysis | 6.25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 2 Activity

Activity

1% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
1% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 3 Activity

Activity

13% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
13% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 4 Activity

Activity

30% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
30% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 5 Activity

Activity

46% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
46% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 6 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis